Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet

Lipids in Health and Disease

Juan C Díaz-Zagoya¹  Deysi Y Bermúdez-Ocaña³  Teresa Ramón-Frías²  Marco A Juárez-Oropeza¹  María Teresa Espinosa-García¹  Carlos A Tovilla-Zárate³  Isela E Juárez-Rojop²  Ma Antonia Jiménez-Santos³ 

[1] Departamento de Bioquímica, Facultad de Medicina, UNAM, México, D.F, México;Centro de Investigación, DACS, Universidad Juárez Autónoma de Tabasco (UJAT), Villahermosa, Tabasco 86150, México;División Académica Multidisciplinaria de Comalcalco, Universidad Juárez Autónoma de Tabasco, Comalcalco, Tabasco, México

关键词: Hypercholesterolemia;    Atorvastatin;    Coenzyme Q₁₀;   

Others  :  811653
DOI  :  10.1186/1476-511X-13-22

 received in 2013-12-06, accepted in 2014-01-14,  发布年份 2014

【 摘 要 】

Background

The aim of this study was to evaluate the actions of coenzyme Q₁₀ (CoQ₁₀) on rats with a cholesterol-rich diet (HD) and high doses of atorvastatin (ATV, 0.2, 0.56 or 1.42 mg/day).

Methods

Two experiments were done, the first one without coenzyme Q₁₀ supplementation. On the second experiment all groups received coenzyme Q₁₀ 0.57 mg/day as supplement. After a 6-week treatment animals were sacrificed, blood and liver were analyzed and liver mitochondria were isolated and its oxygen consumption was evaluated in state 3 (phosphorylating state) and state 4 (resting state) in order to calculate the respiratory control (RC).

Results

HD increased serum and hepatic cholesterol levels in rats with or without CoQ₁₀. ATV reduced these values but CoQ₁₀ improved even more serum and liver cholesterol. Triacylglycerols (TAG) were also lower in blood and liver of rats with ATV + CoQ₁₀. HDL-C decreased in HD rats. Treatment with ATV maintained HDL-C levels. However, these values were lower in HD + CoQ₁₀ compared to control diet (CD) + CoQ₁₀. RC was lessened in liver mitochondria of HD. The administration of ATV increased RC. All groups supplemented with CoQ₁₀ showed an increment in RC. In conclusion, the combined administration of ATV and CoQ₁₀ improved biochemical parameters, liver function and mitochondrial respiration in hypercholesterolemic rats.

Conclusions

Our results suggest a potential beneficial effect of CoQ₁₀ supplementation in hypercholesterolemic rats that also receive atorvastatin. This beneficial effect of CoQ₁₀ must be combined with statin treatment in patient with high levels of cholesterol.

【 授权许可】

   
2014 Jiménez-Santos et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Tamaki N, Ueno H, Morinaga Y, Shiiya T, Nakazato M: Ezetimibe ameliorates atherosclerotic and inflammatory markers, atherogenic lipid profiles, insulin sensitivity, and liver dysfunction in Japanese patients with hypercholesterolemia. J Atheroscler Thromb 2012, 19:532-538.
• [2]Khatibzadeh S, Farzadfar F, Oliver J, Ezzati M, Moran A: Worldwide risk factors for heart failure: A systematic review and pooled analysis. Int J Cardiol 2013, 168:1186-1194.
• [3]Gutiérrez J, Rivera J, Shamah T, Villalpando S, Cuevas L, Romero M, Hernández M: Encuesta Nacional de Salud y Nutrición. México: Resultados nacionales. Cuernavaca, México. Instituto Nacional de Salud Pública; 2012.
• [4]Gómez E, Gisbert J, Moreno J, García L, Moreno R: A pilot study of atorvastatin treatment in dyslipemic non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006, 23:1643-1647.
• [5]Catapano AL, Reiner Z, Backer G, Grahan I, Taskinen M-R, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Perrone Filardi P, Riccardi G, Storey R, Wood D: ESC/EAS guidelines for the management of dyslipidaemias. The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217S:S1-S44.
• [6]Stone NJ, Robinson J, Lichtenstein AH, Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013. doi:pii: S0735-1097(13)06031-2
• [7]Bookstaver D, Nancy P, Pharm B, Hatzigeorgiou C: Effect of Coenzyme Q10 supplementation on statin-Induced myalgias. Am J Cardiol 2012, 110:526-529.
• [8]Wyman M, Leonard M, Morledge T: Coenzyme Q10: a therapy for hypertension and statin-induced myalgia? Cleve Clin J Med 2010, 77:435-442.
• [9]Díaz-Zagoya JC, Asenjo , Barrón JC, Cárdenas R, Martínez F, Juárez-Oropeza MA: Comparative toxicity of high doses of vastatins currently used by clinicians, in CD-1 male mice fed with a hypercholesterolemic diet. Life Sci 1999, 65:947-956.
• [10]Uličná O, Vančová O, Waczulíková I, Božek P, Sikurová L, Bada V, Kucharská J: Liver mitochondrial respiratory function and coenzyme Q content in rats on a hypercholesterolemic diet treated with atorvastatin. Physiol Res 2012, 61:185-193.
• [11]Kang MS, Yang HM, Kang JY, Ryou SH, Kang JS: Effect of coenzyme Q10 and Ardisia japonica Blume on plasma and liver lipids, platelet aggregation, and erythrocyte Na efflux channels in simvastatin-treated guinea pigs. Nutr Res Pract 2012, 6:414-420.
• [12]Ascaso JF, Fernández-Cruz A, González Santos P, Hernández Mijares A, Mangas Rojas A, Millán J, Felipe Pallardo L, Pedro-Botet J, Pérez-Jiménez F, Pía G, Pintó X, Plaza I, Rubiés-Prat J: HDL Forum Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum. Am J Cardiovasc Drugs 2004, 4:299-314.
• [13]Chapman M, Goff W, Guerin M, Kontush A: Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors. Eur Heart J 2010, 31:149-164.
• [14]Mabuchi H, Nohara A, Kobayashi J, Kawashiri M, Katsuda S, Inazu A, Koizumi J: Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study. Atherosclerosis 2007, 195:182-189.
• [15]Singh IM, Shishehbor MH, Ansell BJ: High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007, 298:786-798.
• [16]Langsjoen P, Langsjoen A: The clinical use of HMG-CoA reductase inhibitors and the associated depletion of coenzyme Q10, A review of animal and human publications. Biofactors 2003, 18:101-11.
• [17]Littarru GP, Tiano L: Bioenergetic and antioxidant properties of coenzyme Q10: recent developments. Mol Biotechnol 2007, 37:31-37.
• [18]Mahmoud M, El-Nagar M, El-Bassossy H: Anti-inflammatory effect of atorvastatin on vascular reactivity and insulin resistance in fructose fed rats. Arch Pharm Res 2012, 1:155-162.
• [19]Schroeder M, Belloto R, Hudson R, McInerney M: Effects of antioxidants coenzyme Q10 and lipoic acid on interleukin-1 beta-mediated inhibition of glucose-stimulated insulin release from cultured mouse pancreatic islets. Immunopharmacol Immunotoxicol 2005, 27:109-122.
• [20]Bhardwaj S, Selvarajah S, Schneider EB: Muscular effects of statins in the elderly female: a review. Clin Interv Aging 2013, 8:47-59.
• [21]Kumar A, Kaur H, Devi P, Mohan V: Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacol Ther 2009, 124:259-268.
• [22]Kučera O, Lotková H, Staňková P, Podhola M, Roušar T, Mezera V, Cervinková Z: Is rat liver affected by non-alcoholic steatosis more susceptible to the acute toxic effect of thioacetamide? Int J Exp Pathol 2011, 92:281-289.
• [23]Abbas AM, Sakr HF: Simvastatin and vitamin E effects on cardiac and hepatic oxidative stress in rats fed on high fat diet. J Physiol Biochem 2013, 69:737-50.
• [24]Ferre P: The biology of Peroxisome Proliferator–Activated Receptors relationship with lipid metabolism and insulin sensitivity. Diabetes 2004, 53:43-50.
• [25]Murrow J, Sher S, Ali S, Uphoff I, Patel R, Porkert M, Le N, Jones D, Quyyumi A: The differential effect of statins on oxidative stress and endothelial function: atorvastatin versus pravastatin. J Clin Lipidol 2012, 6:42-49.
• [26]Yuan G, Wang J, Hegele RA: Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ 2006, 174:1124-1129.
• [27]Boone LR, Brooks PA, Niesen MI, Ness GC: Mechanism of resistance to dietary cholesterol. J Lipids 2011, 2011:1012-1042.
• [28]Goldstein JL, DeBose-Boyd RA, Brown MS: Protein sensors for membrane sterols. Cell 2006, 124:35-46.
• [29]Yang C, McDonald J, Patel A, Zhang Y, Umetani M, Xu F, Westover E, Covey D, Mangelsdorf J, Cohen J, Hobbs H: Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem 2006, 281:27816-27826.
• [30]Schmelzer C, Okun J, Haas D, Higuch K, Sawashita J, Mori M, Döring F: The reduced form of coenzyme Q10 mediates distinct effects on cholesterol metabolism at the transcriptional and metabolite level in SAMP1 mice. IUBMB Life 2010, 62:812-818.
• [31]Bjorkhem I, Meaney S, Diczfalusy U: Oxysterols in human circulation: which role do they have? Curr Opin Lipidol 2002, 13:247-253.
• [32]Mari A, DeFronzo RA: Predominant role of reduced beta-cell sensitivity to glucose over insulin resistance in impaired glucose tolerance. Diabetologia 2003, 46:1211-1219.
• [33]Wei Y, Rector R, Thyfault J, Ibdah J: Nonalcoholic fatty liver disease and mitochondrial dysfunction. World J Gastroenterol 2008, 14:193-199.
• [34]Marcoff L, Paul D, Thompson M: The role of coenzyme Q10 in statin-associated myopathy. J Am Coll Cardiol 2007, 49:2231-2237.
• [35]Kwak HB, Thalacker-Mercer A, Anderson EJ, Lin CT, Kane DA, Lee NS, Cortright RN, Bamman MM, Neufer PD: Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. Free Radic Biol Med 2012, 52:198-207.
• [36]Uyuklu M, Meiselman HJ, Baskurt OK: Effect of decreased plasma cholesterol by atorvastatin treatment on erythrocyte mechanical properties. Clin Hemorheol Microcirc 2007, 36:25-33.
• [37]Deichmann R, Lavie C, Andrews S: Coenzyme Q10 and statin-induced mitochondrial dysfunction. Ochsner J. 2010, 10:16-21.
• [38]Kettawan A, Takahashi T, Kongkachuichai R, Charoenkiatkul S, Kishi T, Okamoto T: Protective effects of Coenzyme Q10 on decreased oxidative stress resistance induced by simvastatin. J Clin Biochem Nutr 2007, 40:194-202.
• [39]Kimura Y, Hyogo H, YamagishI S, Takeuchi M, Ischitobi T, Nabeshima Y, Arihiro K, Chayama K: Atorvastatin decreases serum levels of advanced glycation end products (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as biomarker for the attenuation of NASH. J Gastroenterol 2010, 45:750-757.
• [40]Kapoor P, Kapoor AK: Coenzyme Q10: A novel molecule. JIACM 2013, 14:37-45.
• [41]Caso G, Kelly P, McNurlan MA, Lawson WE: Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 2007, 99:1409-1412.
• [42]Folch J, Lee M, Sloane Stanley GH: A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 1957, 226:497-509.
• [43]Bradford M: A Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
• [44]Estabrook R: Mitochondrial respiratory control and the polarographic measurement of the ADP: O ratios. In Methods in Enzymology. Oxidation and Phosphorylation. Edited by Estabrook RW, Pullman ME. New York: Academic Press Inc; 1967:41-47.